Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission

Critical Care Medicine

Volumn 30, Issue 11, 2002, Pages 2413-2419

  Teres, Daniel ^a   Rapoport, John ^a   Lemeshow, Stanley ^a   Kim, Sunny ^a   Akhras, Kasem ^a  

^a M and V 1 ^*  (United States)

Author keywords

Economic effect of therapy; Intensive care unit; Probability of survival; Resource use; Sepsis; Severity of illness

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEPSIS; SHOCK; SURVIVAL;

EID: 0036852019     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200211000-00002     Document Type: Article

References (30)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
2. Sands KE, Bates DW, Lanken PN, et al: Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997; 278:234-240
3. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123
4. Brun-Buisson C, Doyon P, Cadet J, et al: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units. JAMA 1995; 274:968-974
5. Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000; 26(Suppl 1):S64-S74
6. Edbrooke DL, Hibbert CL, Kingsley JM, et al: The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999; 27:1760-1767
7. Annane D, Sebille V, Troche G, et al: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038-1045
8. Le Gall JR, Lemeshow S, Leleu G, et al: Customized probability models for early severe sepsis in adult intensive care patients. JAMA 1995; 273:644-650
9. Knaus WA, Harrell FE, Fisher CJ, et al: The clinical evaluation of new drugs for sepsis: A prospective study design based on survival analysis. JAMA 1993; 270:1233-1241
10. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
11. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. Intensive Care Med 1996; 22:707-710
12. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
13. Wheeler AP, Bernard GR: Treating patients with severe sepsis. New Engl J Med 1999; 340:207-214
14. Bernard GR, Vincent J-L, Laterre P-F, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
15. Abraham E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28:S31-S33
16. Cook SF, Visscher WA, Hobbs CL, et al: Project IMPACT: Preliminary results from a pilot validity study of a new observational database. Abstr. Crit Care Med 1999; 27(Suppl):A36
17. Lemeshow S, Teres D, Klar J, et al: Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993; 270:2478-2486
18. Le Gall J-R, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-2963
19. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086
20. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
21. Rapoport J, Teres D, Lemeshow S, et al: Explaining variability of cost using a severity-of-illness measure for ICU patients. Med Care 1990; 28:338-348
22. Detsky AS, Strickler SC, Mulley AG, et al: Prognosis, survival, and the expenditure of hospital resources for patients in an intensive care unit. N Engl J Med 1981; 305:6
23. Marshall JC: Clinical trials of mediator-directed therapy of sepsis: What have we learned? Intensive Care Med 2000; 26: S75-S83
24. Wagner DP, Wineland TD, Knaus WA: The hidden costs of treating severely ill patients: Charges and resource consumption in an intensive care unit. Health Care Financ Rev 1983; 5:81-86
25. Norris C, Jacobs P, Rapoport J, et al: ICU and non-ICU cost per day. Can J Anaesth 1995; 42:192-196
26. Russell LB: Technology in Hospitals: Medical Advances and their Diffusion. Washington DC, The Brookings Institution, 1979
27. Knaus WA, Thibault GE: Intensive care units today. In: Critical Issues in Medical Technology. McNeil BJ, Cravalho EG (Eds). Boston, Auburn House, 1982, pp 193-215
28. Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs and attributable mortality. JAMA 1995; 271:1598-1601
29. Chalfin DB, Holbein ME, Fein AM, et al: Cost-effectiveness of monoclonal antibodies to Gram-negative endotoxin in the treatment of Gram-negative sepsis I the ICU patients. JAMA 1993; 269:249-254
30. Knaus WA, Harrell FE, LaBrecque JF, et al: Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. Crit Care Med 1996; 24:46-56